Tff Pharmaceuticals, Inc. Stock Price, News & Analysis

TFF Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that CEO Harlan Weisman will partake in a Fireside Chat at the 35th Annual Roth Conference from March 12-14, 2023, at The Ritz Carlton, Laguna Niguel, CA. Weisman will discuss the company's patented Thin Film Freezing technology, which enhances drug delivery and bioavailability. The chat is scheduled for March 13, 2023, at 10:30 AM PT, hosted by Jonathan Aschoff of ROTH Capital Partners. TFF Pharmaceuticals aims to reformulate medicines into dry powder forms, improving efficacy and safety. The event will feature one-on-one meetings with management and a replay accessible for 90 days on their website.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) announced the appointment of Dr. Harlan Weisman as permanent CEO and Dr. Zamaneh Mikhak as Chief Medical Officer. Both leaders will discuss the company’s corporate strategy and 2023 objectives during a conference call scheduled for February 16, 2023. Dr. Mikhak will also highlight the potential of TFF’s Inhaled Voriconazole and Inhaled Tacrolimus programs, leveraging the patented Thin Film Freezing technology. This technology transforms compounds into dry powder formulations, improving administration efficacy.

TFF Pharmaceuticals (NASDAQ: TFFP) has appointed Dr. Zamaneh Mikhak as its new Chief Medical Officer. Dr. Mikhak, a physician-scientist with extensive experience in clinical development, will oversee the clinical pipeline, including the Inhaled Voriconazole and Inhaled Tacrolimus programs. Her expertise is expected to enhance clinical development efforts and expand the company's product pipeline. Dr. Mikhak's background includes leadership roles at various pharmaceutical companies, contributing to successful clinical trials and drug development strategies.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) announces that Glenn Mattes will step down as CEO and Board Member, effective December 5, 2022. Dr. Harlan F. Weisman, Vice Chairman of the Board, has been appointed Interim CEO. Under Mattes’ leadership, TFFP advanced proprietary pipeline candidates, completed its IPO, and expanded collaborations in biotechnology. Dr. Weisman brings over 30 years of experience, confident in the company’s pipeline growth and the potential of its Thin Film Freezing technology, which enhances drug delivery across various routes.

TFF Pharmaceuticals (NASDAQ: TFFP) has successfully closed its underwritten offering of 10,675,001 shares and warrants for 5,337,501 shares of common stock, including an option exercise by underwriters. The offering was priced at $1.15 per share, yielding approximately $12.3 million in gross proceeds. The funds will be allocated towards clinical trials, research, and working capital. The company focuses on transforming medicines using its Thin Film Freezing technology, enhancing drug stability and efficacy.

TFF Pharmaceuticals (NASDAQ: TFFP) has announced a $10.675 million underwritten offering, consisting of 9,282,609 shares of common stock and accompanying warrants. Each share, priced at $1.15, is paired with a warrant to acquire one additional share for every two purchased. The company aims to utilize the proceeds for clinical trials, research, and general corporate purposes. The offering is expected to close on November 22, 2022, with a provision for underwriters to purchase an additional 15% of shares within 45 days.

TFF Pharmaceuticals (NASDAQ: TFFP) announced a public offering of common stock and warrants, all being sold by the company itself. The offering includes a 45-day option for underwriters to purchase an additional 15% of the shares and warrants. The final terms will depend on market conditions, and the offering is expected to price on November 17, 2022. Proceeds from the offering will be used for working capital and general corporate purposes. The company has filed a preliminary prospectus supplement with the SEC.

TFF Pharmaceuticals (TFFP) announced third quarter 2022 results highlighting clinical advancements with Voriconazole Inhalation Powder (TFF VORI) in a compassionate use program. Two patients showed stabilized lung function and negative cultures for aspergillus. The company revealed a collaboration with Aptar Pharma to explore intranasal dry powder therapies. Financially, TFFP reported cash reserves of $13.1 million and a net loss of $7.3 million for Q3 2022, a slight improvement from $8.7 million in the prior year. R&D expenses dropped to $4.0 million, while G&A expenses rose to $3.3 million.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) is set to release its financial results for Q3 2022 on November 14, 2022. The conference call will occur at 4:30 PM ET, followed by a Q&A session with investors. TFF Pharmaceuticals focuses on innovative drug products using its patented Thin Film Freezing technology, which enhances drug delivery and bioavailability. The platform can reformulate existing drugs into dry powders for inhalation, improving efficacy and safety. Currently, TFF has two lead candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder.